ICU Medical (ICUI)
Market Price (9/14/2026): $156.7 | Market Cap: $3.9 BilSector: Health Care | Industry: Health Care Supplies
ICU Medical (ICUI)
Market Price (9/14/2026): $156.7Market Cap: $3.9 BilSector: Health CareIndustry: Health Care Supplies
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 11% Low stock price volatilityVol 12M is 36% Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, and Digital Health & Telemedicine. Themes include Oncology Treatments, Geriatric Care, Show more. | Weak multi-year price returns2Y Excs Rtn is -45%, 3Y Excs Rtn is -60% | Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 47x, P/EPrice/Earnings or Price/(Net Income) is 130x Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -9.0%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -1.9% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -3.4% Key risksICUI key risks include [1] an FDA warning letter and potential legal action over unauthorized modifications to its infusion pumps, Show more. |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 11% |
| Low stock price volatilityVol 12M is 36% |
| Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, and Digital Health & Telemedicine. Themes include Oncology Treatments, Geriatric Care, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -45%, 3Y Excs Rtn is -60% |
| Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 47x, P/EPrice/Earnings or Price/(Net Income) is 130x |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -9.0%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -1.9% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -3.4% |
| Key risksICUI key risks include [1] an FDA warning letter and potential legal action over unauthorized modifications to its infusion pumps, Show more. |
Qualitative Assessment
AI Analysis | Feedback
ICU Medical (ICUI) stock has gained about 15% since 5/31/2026 because of the following key factors:
1. Strong Fiscal Q2 2026 Earnings Beat and Upgraded Fiscal Year 2026 Guidance.
ICU Medical reported robust fiscal Q2 2026 results on August 6, 2026, for the period ending June 30, 2026. The company announced an adjusted diluted EPS of $2.37, significantly beating the consensus estimate of $1.91 by 24.08%. Quarterly revenue also surpassed expectations, reaching $548 million against an anticipated $533.44 million. Furthermore, ICU Medical raised and narrowed its fiscal year 2026 adjusted EBITDA guidance to a range of $415 million to $435 million (from $400 million to $430 million) and adjusted EPS guidance to $8.60 to $9.00 (from $7.75 to $8.45). The company also increased its full-year adjusted gross margin expectation to approximately 41.5%.
2. Robust Organic Growth in Core Product Segments.
The company demonstrated strong underlying business performance, with key product lines exhibiting significant organic growth in fiscal Q2 2026. Specifically, the Infusion Systems segment achieved an impressive 12% organic growth, while the Consumables segment grew 5% organically. This strength in core product categories contributed to the overall positive financial results and investor confidence.
Show more
ICU Medical (ICUI) stock has gained about 15% since 5/31/2026 because of the following key factors:
1. Strong Fiscal Q2 2026 Earnings Beat and Upgraded Fiscal Year 2026 Guidance.
ICU Medical reported robust fiscal Q2 2026 results on August 6, 2026, for the period ending June 30, 2026. The company announced an adjusted diluted EPS of $2.37, significantly beating the consensus estimate of $1.91 by 24.08%. Quarterly revenue also surpassed expectations, reaching $548 million against an anticipated $533.44 million. Furthermore, ICU Medical raised and narrowed its fiscal year 2026 adjusted EBITDA guidance to a range of $415 million to $435 million (from $400 million to $430 million) and adjusted EPS guidance to $8.60 to $9.00 (from $7.75 to $8.45). The company also increased its full-year adjusted gross margin expectation to approximately 41.5%.
2. Robust Organic Growth in Core Product Segments.
The company demonstrated strong underlying business performance, with key product lines exhibiting significant organic growth in fiscal Q2 2026. Specifically, the Infusion Systems segment achieved an impressive 12% organic growth, while the Consumables segment grew 5% organically. This strength in core product categories contributed to the overall positive financial results and investor confidence.
3. Positive Analyst Revisions and Elevated Price Targets.
Following the strong fiscal Q2 2026 earnings report, several Wall Street analysts reiterated or assigned "Buy" ratings and increased their price targets for ICU Medical. For instance, Raymond James maintained a "Buy" rating with a $200 target, Piper Sandler raised its target from $163 to $195, BTIG increased its target from $170 to $200, and Needham raised its target from $165 to $187. The average analyst price target for ICUI stood at $192.80 as of September 4, 2026, indicating a forecasted upside of 15.05% from the stock's price of $167.58.
Show less
Stock Movement Drivers
Fundamental Drivers
The 15.6% change in ICUI stock from 5/31/2026 to 9/13/2026 was primarily driven by a 79.7% change in the company's P/E Multiple.| (LTM values as of) | 5312026 | 9132026 | Change |
|---|---|---|---|
| Stock Price ($) | 135.39 | 156.48 | 15.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 2,157 | 2,160 | 0.1% |
| Net Income Margin (%) | 2.1% | 1.4% | -35.2% |
| P/E Multiple | 72.4 | 130.0 | 79.7% |
| Shares Outstanding (Mil) | 25 | 25 | -0.9% |
| Cumulative Contribution | 15.6% |
Market Drivers
5/31/2026 to 9/13/2026| Return | Correlation | |
|---|---|---|
| ICUI | 15.6% | |
| Market (SPY) | 1.0% | 25.9% |
| Sector (XLV) | 10.6% | 39.6% |
Fundamental Drivers
The 3.9% change in ICUI stock from 2/28/2026 to 9/13/2026 was primarily driven by a 4146.9% change in the company's Net Income Margin (%).| (LTM values as of) | 2282026 | 9132026 | Change |
|---|---|---|---|
| Stock Price ($) | 150.58 | 156.48 | 3.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 2,231 | 2,160 | -3.2% |
| Net Income Margin (%) | 0.0% | 1.4% | 4146.9% |
| P/E Multiple | 5,078.6 | 130.0 | -97.4% |
| Shares Outstanding (Mil) | 25 | 25 | -1.2% |
| Cumulative Contribution | 3.9% |
Market Drivers
2/28/2026 to 9/13/2026| Return | Correlation | |
|---|---|---|
| ICUI | 3.9% | |
| Market (SPY) | 11.7% | 41.4% |
| Sector (XLV) | 3.6% | 44.6% |
Fundamental Drivers
The 22.6% change in ICUI stock from 8/31/2025 to 9/13/2026 was primarily driven by a 36.6% change in the company's P/S Multiple.| (LTM values as of) | 8312025 | 9132026 | Change |
|---|---|---|---|
| Stock Price ($) | 127.66 | 156.48 | 22.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 2,373 | 2,160 | -9.0% |
| P/S Multiple | 1.3 | 1.8 | 36.6% |
| Shares Outstanding (Mil) | 25 | 25 | -1.4% |
| Cumulative Contribution | 22.6% |
Market Drivers
8/31/2025 to 9/13/2026| Return | Correlation | |
|---|---|---|
| ICUI | 22.6% | |
| Market (SPY) | 19.5% | 38.0% |
| Sector (XLV) | 21.9% | 41.1% |
Fundamental Drivers
The 7.9% change in ICUI stock from 8/31/2023 to 9/13/2026 was primarily driven by a 19.0% change in the company's P/S Multiple.| (LTM values as of) | 8312023 | 9132026 | Change |
|---|---|---|---|
| Stock Price ($) | 145.03 | 156.48 | 7.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 2,294 | 2,160 | -5.9% |
| P/S Multiple | 1.5 | 1.8 | 19.0% |
| Shares Outstanding (Mil) | 24 | 25 | -3.7% |
| Cumulative Contribution | 7.9% |
Market Drivers
8/31/2023 to 9/13/2026| Return | Correlation | |
|---|---|---|
| ICUI | 7.9% | |
| Market (SPY) | 75.7% | 42.5% |
| Sector (XLV) | 30.0% | 39.0% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| ICUI Return | 11% | -34% | -37% | 56% | -8% | 10% | -27% |
| Peers Return | 5% | -25% | -2% | -12% | -7% | 10% | -31% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 11% | 102% |
Monthly Win Rates [3] | |||||||
| ICUI Win Rate | 42% | 25% | 33% | 50% | 25% | 67% | |
| Peers Win Rate | 48% | 42% | 48% | 53% | 53% | 58% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 44% | |
Max Drawdowns [4] | |||||||
| ICUI Max Drawdown | -16% | -45% | -61% | -17% | -37% | -27% | |
| Peers Max Drawdown | -20% | -38% | -30% | -25% | -31% | -23% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: BAX, BDX, TFX, EW, MDT. See ICUI Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 9/11/2026 (YTD)
How Low Can It Go
| Event | ICUI | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -21.7% | -18.8% |
| % Gain to Breakeven | 27.8% | 23.1% |
| Time to Breakeven | 426 days | 79 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -52.9% | -9.5% |
| % Gain to Breakeven | 112.4% | 10.5% |
| Time to Breakeven | 308 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -15.5% | -6.7% |
| % Gain to Breakeven | 18.3% | 7.1% |
| Time to Breakeven | 45 days | 31 days |
| 2020 COVID-19 Crash | ||
| % Loss | -26.0% | -33.7% |
| % Gain to Breakeven | 35.1% | 50.9% |
| Time to Breakeven | 31 days | 140 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -29.8% | -12.2% |
| % Gain to Breakeven | 42.3% | 13.9% |
| Time to Breakeven | 186 days | 62 days |
| 2011 US Debt Ceiling Crisis & European Contagion | ||
| % Loss | -16.3% | -17.9% |
| % Gain to Breakeven | 19.5% | 21.8% |
| Time to Breakeven | 45 days | 123 days |
In The Past
ICU Medical's stock fell -21.7% during the 2025 US Tariff Shock. Such a loss loss requires a 27.8% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | ICUI | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -21.7% | -18.8% |
| % Gain to Breakeven | 27.8% | 23.1% |
| Time to Breakeven | 426 days | 79 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -52.9% | -9.5% |
| % Gain to Breakeven | 112.4% | 10.5% |
| Time to Breakeven | 308 days | 24 days |
| 2020 COVID-19 Crash | ||
| % Loss | -26.0% | -33.7% |
| % Gain to Breakeven | 35.1% | 50.9% |
| Time to Breakeven | 31 days | 140 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -29.8% | -12.2% |
| % Gain to Breakeven | 42.3% | 13.9% |
| Time to Breakeven | 186 days | 62 days |
| 2008-2009 Global Financial Crisis | ||
| % Loss | -39.8% | -53.4% |
| % Gain to Breakeven | 66.0% | 114.4% |
| Time to Breakeven | 316 days | 1085 days |
| Summer 2007 Credit Crunch | ||
| % Loss | -24.6% | -8.6% |
| % Gain to Breakeven | 32.7% | 9.5% |
| Time to Breakeven | 717 days | 47 days |
In The Past
ICU Medical's stock fell -21.7% during the 2025 US Tariff Shock. Such a loss loss requires a 27.8% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About ICU Medical (ICUI)
ICU Medical, Inc. (ICUI) is a global medical technology company that develops, manufactures, and sells a comprehensive range of medical devices primarily used in infusion therapy and critical care applications. The company's mission is to enhance patient safety and clinical outcomes across various healthcare environments by providing innovative solutions.
The company's infusion therapy products include needlefree connectors (e.g., MicroClave, NanoClave), disinfecting caps (e.g., SwabCap), and specialized hemodialysis connectors (e.g., Tego, ClearGuard HD). ICU Medical also offers closed system transfer devices (e.g., ChemoClave, ChemoLock) and compounding systems (e.g., Diana) for the safe handling of hazardous drugs. Additionally, it provides a full line of IV therapy solutions, diluents, and irrigation products, alongside smart infusion pumps like the Plum 360 and LifeCare PCA, complemented by medication safety software such as ICU Medical MedNet for integrated medication management.
In the critical care sector, ICUI supplies advanced hemodynamic monitoring systems (e.g., Cogent, CardioFlo), various cardiac output and venous oximetry catheters, blood pressure transducers (e.g., Transpac), and closed blood sampling and conservation systems (e.g., SafeSet). These critical care products are essential for monitoring and managing acutely ill patients. ICU Medical primarily serves acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, including outpatient clinics, home health care providers, and long-term care facilities.
AI Analysis | Feedback
- A specialized Baxter International focused on IV therapy, smart infusion pumps, and critical care monitoring for hospitals.
- Like Becton Dickinson (BD), but concentrated specifically on advanced IV medication delivery, infusion safety software, and critical care monitoring systems for healthcare facilities.
AI Analysis | Feedback
Infusion Therapy Devices
Develops various products including needlefree connectors (MicroClave, NanoClave), catheter patency devices, disinfecting caps (SwabCap, SwabTip), and hemodialysis connectors (Tego, ClearGuard HD).
Hazardous Drug Management Systems
Offers closed system transfer devices (ChemoClave, ChemoLock) and the Diana hazardous drug compounding system for the safe handling and preparation of hazardous medications.
IV Solutions and Diluents
Provides a range of intravenous solutions such as sodium chloride, dextrose, balanced electrolytes, and sterile water for hydration and medication dilution.
Irrigation Solutions
Supplies various irrigation solutions including sodium chloride, sterile water, and physiologic solutions, available in flexible containers and pour bottles.
Infusion Pumps
Manufactures infusion pumps under the Plum 360 and LifeCare PCA brands for controlled delivery of fluids, medications, and nutrients.
IV Medication Safety Software
Offers ICU Medical MedNet, an enterprise-class medication management platform that connects smart pumps to hospital IT systems for enhanced safety and workflow.
Critical Care Monitoring Systems
Includes hemodynamic monitoring systems (Cogent 2-in-1, CardioFlo), cardiac output monitoring catheters, venous oximetry catheters, and blood pressure transducers.
Blood Sampling and Conservation Systems
Provides SafeSet closed blood sampling and conservation systems designed for efficient and safe blood management.
Professional Services
Offers related professional services to support the implementation, integration, and optimization of its medical devices and software solutions.
AI Analysis | Feedback
Major Customers of ICU Medical (ICUI)
ICU Medical, Inc. primarily sells its products to other companies and organizations within the healthcare sector. Based on the company description, its major customers include:- Acute care hospitals
- Wholesalers
- Ambulatory clinics
- Alternate site facilities, which encompass outpatient clinics, home health care providers, and long-term care facilities
AI Analysis | Feedback
AI Analysis | Feedback
Vivek Jain, Chairman & Chief Executive Officer
Mr. Jain joined ICU Medical in February 2014 as Chairman and Chief Executive Officer. Prior to his role at ICU Medical, he was President of the Procedural Solutions division at CareFusion Corporation, where he was responsible for a significant portfolio of medical disposables products. His career also includes leadership positions as Executive Vice President of Strategy and Corporate Development at Cardinal Health, and senior roles at Philips Medical Systems. Earlier in his career, he spent twelve years at J.P. Morgan, ultimately serving as Co-Head of Global Healthcare Investment Banking. Mr. Jain currently serves as an Independent Director for Envista Holdings Corp.Brian Bonnell, Chief Financial Officer and Treasurer
Mr. Bonnell has served as ICU Medical's Chief Financial Officer and Treasurer since March 2020. Before this, he was the company's Corporate Vice President, Finance, from May 2018 to March 2020. His prior experience includes serving as Treasurer and Head of Financial Planning and Analysis at Alere Inc. from May 2015 to December 2017. Before joining Alere, Mr. Bonnell held various financial roles at CareFusion Corporation, including Senior Vice President, Tax and Treasurer.Daniel Woolson, President
Mr. Woolson has held the position of Corporate Vice President and General Manager, Infusion Systems at ICU Medical since February 2017. His career includes various senior management and consulting roles at notable companies such as Vyaire, BD, CareFusion, Cardinal Health, and McKinsey & Company, spanning from 1999 to 2016.Christian Voigtlander, Chief Operating Officer
Mr. Voigtlander has served as ICU Medical's Chief Operating Officer since January 2018. From February 2017 to January 2018, he was the Corporate Vice President, Business Development and General Manager, Infusion Solutions. Prior to May 2015, Mr. Voigtlander held various positions at CareFusion, where his last role was Senior Vice President, Business Development and Strategy.Virginia Sanzone, Corporate Vice President, General Counsel and Secretary
Ms. Sanzone has been ICU Medical's Corporate Vice President, General Counsel and Secretary, as well as Compliance Officer, since January 2018. Before this, she served as the company's Vice President, General Counsel from August 2015 to January 2018. Her experience before joining ICU Medical includes various roles at CareFusion, where she most recently served as Senior Vice President, Associate General Counsel - Business Segments & Americas.AI Analysis | Feedback
-
Regulatory Compliance and Product Liability: As a developer and manufacturer of medical devices for infusion therapy and critical care, ICU Medical is subject to extensive and evolving regulations from health authorities worldwide. This includes stringent requirements for product development, manufacturing processes, marketing, and post-market surveillance. Non-compliance could lead to product recalls, regulatory fines, manufacturing suspensions, or even the inability to market certain products. Furthermore, the nature of their products, used in critical patient care, exposes the company to significant product liability risks, where device malfunctions or safety concerns could result in costly litigation, reputational damage, and adverse effects on sales.
-
Intense Competition and Technological Obsolescence: The medical device market, particularly in infusion therapy and critical care, is highly competitive. ICU Medical faces competition from a range of companies, including larger, more diversified medical technology firms. This competition can lead to pricing pressures, demands for increased innovation, and challenges in maintaining market share. Additionally, the rapid pace of technological advancements in healthcare means that ICU Medical's existing products could become obsolete if the company fails to continually innovate and introduce new, more advanced solutions that meet evolving clinical needs and integration requirements, such as those related to electronic health records and connected systems.
-
Healthcare Cost Containment and Reimbursement Pressures: ICU Medical's primary customers are acute care hospitals, ambulatory clinics, and other healthcare facilities. These customers are increasingly operating under significant pressure to reduce costs due to evolving healthcare reimbursement models, government healthcare reforms, and the general trend towards cost containment. This environment can lead to hospitals demanding lower prices for medical devices, delaying capital expenditures, or favoring less expensive alternatives, thereby negatively impacting ICU Medical's sales volumes and profit margins.
AI Analysis | Feedback
The rise of highly accurate and comprehensive non-invasive critical care monitoring technologies poses a clear emerging threat to ICU Medical's portfolio of invasive critical care products. These include their Cogent 2-in-1 and CardioFlo hemodynamic monitoring systems, TDQ and OptiQ cardiac output monitoring catheters, TriOx venous oximetry catheters, and Transpac blood pressure transducers. As non-invasive solutions advance in accuracy and adoption, they could reduce the demand for traditional invasive monitoring devices by offering reduced patient risk, discomfort, and healthcare costs, representing a paradigm shift similar to past disruptions.
AI Analysis | Feedback
AI Analysis | Feedback
For ICU Medical (ICUI), several key drivers are expected to fuel future revenue growth over the next 2-3 years:
- International Expansion: ICU Medical is focusing on geographic expansion, particularly in emerging markets, to leverage its expanded scale after the Smiths Medical acquisition. This strategy includes targeting high-growth regions like EMEA, APAC, Latin America, the Middle East, and Southeast Asia, optimizing sales channels, and broadening distribution networks to reach new and underserved customer bases.
- Product Innovation and Portfolio Diversification: The company is investing in research and development to drive innovation and expand its product offerings beyond core infusion therapy. Specific initiatives include prioritizing next-generation infusion pumps, expanding the NeutraClear and MicroClave lines, upgrading oncology Closed System Transfer Devices (CSTD) like ChemoLock, and growing its presence in temperature management and respiratory care through product refresh cycles scheduled for 2025–2026.
- Growth in Core Consumables and IV Systems Businesses: The consumables business, particularly in oncology, has been a strong performer, with high single-digit growth observed in infusion consumables, oncology, and tracheostomy product lines. Similarly, the IV Systems business has demonstrated double-digit growth in LVP (Large Volume Parenteral) revenue, driven by increased utilization and competitive wins. Management anticipates mid-single-digit sales growth for these segments in the medium term.
- Leveraging Smiths Medical Acquisition for Synergies and Installed Base Recovery: The strategic acquisition of Smiths Medical aims to enhance ICU Medical's market position, expand its product portfolio, and strengthen its global presence. A key focus is on completing the integration of Smiths Medical by 2025, which includes SKU and platform rationalization, consolidated manufacturing, and ERP harmonization to improve gross margins and service levels. Additionally, regaining market share in large capital fleets, such as Medfusion and CADD pumps, is central to driving high-margin disposable pull-through and restoring recurring revenue growth.
AI Analysis | Feedback
Share Repurchases
ICU Medical has not made significant share repurchases over the last 3-5 years. The treasury stock values observed in financial reports suggest minor adjustments, likely related to employee stock plans, rather than a material share repurchase program.
Share Issuance
- The company's issued and outstanding shares increased from 24,518 at December 31, 2024, to 24,688 at December 31, 2025.
- Additional paid-in capital increased to $1,451,146 in 2025 from $1,412,118 in 2024, and from $1,366,493 in 2023 to $1,412,118 in 2024, indicating share issuances.
Inbound Investments
- In Q2 2025, ICU Medical received $200 million in proceeds from the formation of the Otsuka ICU Medical JV, which was entirely used for debt repayment.
Outbound Investments
- On May 1, 2025, ICU Medical disposed of its IV Solutions business through the creation of the Otsuka ICU Medical JV.
- ICU Medical holds a 40% equity investment in the Otsuka ICU Medical JV, leading to a significant increase in investments in unconsolidated affiliates from approximately $3 million in 2024 to $131.6 million in 2025.
Capital Expenditures
- Capital expenditures were $24 million in 2021, $15 million in 2022, $20 million in 2023, and $29 million in 2024.
- For 2025, estimated capital expenditures were in the range of $90 million to $110 million.
- Capital expenditures in 2025 were focused on general maintenance, capacity expansion at facilities, and the placement of revenue-generating infusion pumps with customers internationally.
Peer Outperformance in Health Care Supplies
| Industry | Names | 1Y med | 3Y med | 5Y med | Top 3 by 5Y |
|---|---|---|---|---|---|
| Health Care Distributors | 7 | 7.1% | 86.3% | 123.6% | CAH 402% · MCK 343% · COR 175% |
| Managed Health Care | 8 | 43.7% | -1.3% | 8.2% | OSCR 84% · HQY 57% · ELV 23% |
| Health Care Services | 20 | 18.9% | 44.9% | 0.0% | HIMS 218% · RDNT 172% · DGX 67% |
| Health Care Facilities | 24 | 3.7% | 7.9% | -14.2% | NHC 276% · THC 268% · ENSG 122% |
| Health Care Equipment | 50 | -1.7% | -5.5% | -25.7% | POCI 10800% · UFPT 331% · GKOS 234% |
| Health Care Supplies ← | 12 | 20.8% | -12.1% | -37.9% | LNTH 308% · HAE 51% · MMSI 21% |
| Pharmaceuticals | 62 | -7.4% | 7.7% | -40.7% | LQDA 2457% · INDV 1136% · ETON 1063% |
| Life Sciences Tools & Services | 109 | -1.4% | -25.5% | -71.2% | SNWV 1573% · MEDP 224% · NTRA 174% |
| Health Care Technology | 20 | -31.7% | -52.2% | -78.5% | SPOK 77% · HSTM 3% · VEEV -12% |
| Biotechnology | 362 | 1.6% | -24.8% | -79.6% | DNTH 1632% · CELZ 1272% · ELVN 1222% |
Latest Trefis Analyses
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 110.97 |
| Mkt Cap | 30.5 |
| Rev LTM | 8,991 |
| Op Inc LTM | 1,020 |
| FCF LTM | 1,123 |
| FCF 3Y Avg | 746 |
| CFO LTM | 1,520 |
| CFO 3Y Avg | 1,107 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 12.2% |
| Rev Chg 3Y Avg | 5.1% |
| Rev Chg Q | 9.5% |
| QoQ Delta Rev Chg LTM | 2.3% |
| Op Inc Chg LTM | 11.4% |
| Op Inc Chg 3Y Avg | 9.2% |
| Op Mgn LTM | 10.5% |
| Op Mgn 3Y Avg | 12.9% |
| QoQ Delta Op Mgn LTM | 0.2% |
| CFO/Rev LTM | 17.7% |
| CFO/Rev 3Y Avg | 17.9% |
| FCF/Rev LTM | 13.6% |
| FCF/Rev 3Y Avg | 13.8% |
Price Behavior
| Market Price | $156.48 | |
| Market Cap ($ Bil) | 3.9 | |
| First Trading Date | 03/31/1992 | |
| Distance from 52W High | -16.4% | |
| 50 Days | 200 Days | |
| DMA Price | $167.50 | $145.99 |
| DMA Trend | up | up |
| Distance from DMA | -6.6% | 7.2% |
| 3M | 1YR | |
| Volatility | 39.9% | 36.2% |
| Downside Capture | 106.28 | 116.46 |
| Upside Capture | 138.03 | 116.24 |
| Correlation (SPY) | 29.2% | 39.0% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 1.40 | 1.11 | 0.75 | 1.14 | 1.09 | 1.18 |
| Up Beta | 0.65 | 0.28 | 0.17 | 1.08 | 1.18 | 1.34 |
| Down Beta | 0.35 | 0.63 | 0.58 | 1.38 | 0.84 | 0.88 |
| Up Capture | 174% | 211% | 166% | 114% | 134% | 136% |
| Bmk +ve Days | 10 | 21 | 32 | 68 | 138 | 427 |
| Stock +ve Days | 6 | 19 | 30 | 58 | 117 | 362 |
| Down Capture | 217% | 101% | 46% | 106% | 106% | 106% |
| Bmk -ve Days | 11 | 21 | 32 | 59 | 113 | 324 |
| Stock -ve Days | 14 | 22 | 33 | 68 | 133 | 386 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ICUI | |
|---|---|---|---|---|
| ICUI | 17.2% | 36.2% | 0.50 | - |
| Sector ETF (XLV) | 22.1% | 16.2% | 1.04 | 41.6% |
| Equity (SPY) | 18.3% | 12.8% | 1.03 | 38.9% |
| Gold (GLD) | 19.0% | 29.2% | 0.59 | 11.2% |
| Commodities (DBC) | 48.3% | 20.6% | 1.80 | -29.5% |
| Real Estate (VNQ) | 7.6% | 13.6% | 0.29 | 42.1% |
| Bitcoin (BTCUSD) | -32.4% | 43.8% | -0.77 | 12.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ICUI | |
|---|---|---|---|---|
| ICUI | -4.2% | 41.6% | 0.01 | - |
| Sector ETF (XLV) | 5.5% | 15.2% | 0.18 | 40.0% |
| Equity (SPY) | 12.5% | 17.2% | 0.55 | 42.4% |
| Gold (GLD) | 18.7% | 18.8% | 0.81 | 11.5% |
| Commodities (DBC) | 11.4% | 19.5% | 0.46 | 3.5% |
| Real Estate (VNQ) | 0.7% | 18.9% | -0.07 | 44.0% |
| Bitcoin (BTCUSD) | 9.4% | 52.6% | 0.36 | 22.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ICUI | |
|---|---|---|---|---|
| ICUI | 2.8% | 37.8% | 0.19 | - |
| Sector ETF (XLV) | 10.4% | 16.7% | 0.50 | 39.6% |
| Equity (SPY) | 15.2% | 17.9% | 0.72 | 39.7% |
| Gold (GLD) | 12.3% | 16.3% | 0.62 | 6.0% |
| Commodities (DBC) | 8.7% | 18.1% | 0.39 | 7.7% |
| Real Estate (VNQ) | 4.7% | 20.7% | 0.19 | 34.8% |
| Bitcoin (BTCUSD) | 63.2% | 66.2% | 1.03 | 12.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 9/9/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 8/6/2026 | 10.9% | 10.1% | 0.7% |
| 5/7/2026 | 2.7% | -0.1% | 11.7% |
| 2/19/2026 | 4.9% | 0.7% | -16.3% |
| 11/6/2025 | 8.1% | 6.8% | 9.9% |
| 8/7/2025 | -13.1% | -13.9% | 0.5% |
| 5/8/2025 | -3.2% | -1.6% | -4.6% |
| 2/27/2025 | -2.3% | -5.0% | -6.4% |
| 11/12/2024 | -1.8% | -4.7% | -7.0% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 11 | 9 | 11 |
| # Negative | 13 | 15 | 13 |
| Median Positive | 5.3% | 8.2% | 6.5% |
| Median Negative | -4.9% | -6.6% | -8.2% |
| Max Positive | 24.3% | 21.5% | 33.3% |
| Max Negative | -17.3% | -19.6% | -18.1% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 8/6/2026 | 10.9% | 10.1% | 0.7% |
| 5/7/2026 | 2.7% | -0.1% | 11.7% |
| 2/19/2026 | 4.9% | 0.7% | -16.3% |
| 11/6/2025 | 8.1% | 6.8% | 9.9% |
| 8/7/2025 | -13.1% | -13.9% | 0.5% |
| 5/8/2025 | -3.2% | -1.6% | -4.6% |
| 2/27/2025 | -2.3% | -5.0% | -6.4% |
| 11/12/2024 | -1.8% | -4.7% | -7.0% |
| 8/7/2024 | 24.3% | 21.5% | 33.3% |
| 5/7/2024 | -1.1% | 3.4% | 6.5% |
| 2/27/2024 | 5.3% | -4.0% | -3.7% |
| 11/6/2023 | -17.3% | -19.6% | -15.4% |
| 8/7/2023 | -16.6% | -16.7% | -18.1% |
| 5/8/2023 | 13.6% | 8.2% | 4.3% |
| 2/27/2023 | -3.9% | -9.2% | -12.2% |
| 11/7/2022 | 2.4% | 11.7% | 7.4% |
| 8/8/2022 | -11.6% | -6.6% | -12.1% |
| 5/9/2022 | -8.2% | -10.2% | -12.7% |
| 2/24/2022 | 5.7% | 10.8% | 4.1% |
| 11/3/2021 | 0.1% | -0.4% | -8.2% |
| 8/4/2021 | 0.9% | -1.1% | 6.8% |
| 5/6/2021 | -5.2% | -7.3% | -3.8% |
| 2/25/2021 | -4.9% | -9.2% | -3.8% |
| 11/5/2020 | -0.0% | 3.6% | 4.4% |
| SUMMARY STATS | |||
| # Positive | 11 | 9 | 11 |
| # Negative | 13 | 15 | 13 |
| Median Positive | 5.3% | 8.2% | 6.5% |
| Median Negative | -4.9% | -6.6% | -8.2% |
| Max Positive | 24.3% | 21.5% | 33.3% |
| Max Negative | -17.3% | -19.6% | -18.1% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 08/06/2026 | 10-Q |
| 03/31/2026 | 05/07/2026 | 10-Q |
| 12/31/2025 | 02/19/2026 | 10-K |
| 09/30/2025 | 11/06/2025 | 10-Q |
| 06/30/2025 | 08/07/2025 | 10-Q |
| 03/31/2025 | 05/08/2025 | 10-Q |
| 12/31/2024 | 02/27/2025 | 10-K |
| 09/30/2024 | 11/12/2024 | 10-Q |
| 06/30/2024 | 08/07/2024 | 10-Q |
| 03/31/2024 | 05/07/2024 | 10-Q |
| 12/31/2023 | 02/27/2024 | 10-K |
| 09/30/2023 | 11/06/2023 | 10-Q |
| 06/30/2023 | 08/07/2023 | 10-Q |
| 03/31/2023 | 05/09/2023 | 10-Q |
| 12/31/2022 | 02/27/2023 | 10-K |
| 09/30/2022 | 11/07/2022 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 08/06/2026 | 10-Q |
| 03/31/2026 | 05/07/2026 | 10-Q |
| 12/31/2025 | 02/19/2026 | 10-K |
| 09/30/2025 | 11/06/2025 | 10-Q |
| 06/30/2025 | 08/07/2025 | 10-Q |
| 03/31/2025 | 05/08/2025 | 10-Q |
| 12/31/2024 | 02/27/2025 | 10-K |
| 09/30/2024 | 11/12/2024 | 10-Q |
| 06/30/2024 | 08/07/2024 | 10-Q |
| 03/31/2024 | 05/07/2024 | 10-Q |
| 12/31/2023 | 02/27/2024 | 10-K |
| 09/30/2023 | 11/06/2023 | 10-Q |
| 06/30/2023 | 08/07/2023 | 10-Q |
| 03/31/2023 | 05/09/2023 | 10-Q |
| 12/31/2022 | 02/27/2023 | 10-K |
| 09/30/2022 | 11/07/2022 | 10-Q |
| 06/30/2022 | 08/09/2022 | 10-Q |
| 03/31/2022 | 05/09/2022 | 10-Q |
| 12/31/2021 | 02/25/2022 | 10-K |
| 09/30/2021 | 11/05/2021 | 10-Q |
| 06/30/2021 | 08/04/2021 | 10-Q |
| 03/31/2021 | 05/07/2021 | 10-Q |
| 12/31/2020 | 02/26/2021 | 10-K |
| 09/30/2020 | 11/06/2020 | 10-Q |
| 06/30/2020 | 08/10/2020 | 10-Q |
| 03/31/2020 | 05/08/2020 | 10-Q |
| 12/31/2019 | 03/02/2020 | 10-K |
| 09/30/2019 | 11/12/2019 | 10-Q |
Insider Activity
Updated 9/3/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Sanzone, Virginia Ruth | VP, General Counsel | Direct | Sell | 9032026 | 168.69 | 4,856 | 819,150 | 2,463,524 | Form |
| 2 | Bonnell, Brian Michael | Chief Financial Officer | Direct | Sell | 9012026 | 175.00 | 6,381 | 1,116,675 | 9,810,850 | Form |
| 3 | Bonnell, Brian Michael | Chief Financial Officer | Direct | Sell | 8312026 | 172.79 | 9,307 | 1,608,143 | 10,789,437 | Form |
| 4 | Woolson, Daniel | VP, GM-Infusion Capital | Direct | Sell | 8132026 | 181.33 | 5,417 | 982,265 | 3,093,852 | Form |
| 5 | Sousa, Ben | Chief Information Officer | Direct | Sell | 8122026 | 178.32 | 2,250 | 401,209 | 548,498 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Sanzone, Virginia Ruth | VP, General Counsel | Direct | Sell | 9032026 | 168.69 | 4,856 | 819,150 | 2,463,524 | Form |
| 2 | Bonnell, Brian Michael | Chief Financial Officer | Direct | Sell | 9012026 | 175.00 | 6,381 | 1,116,675 | 9,810,850 | Form |
| 3 | Bonnell, Brian Michael | Chief Financial Officer | Direct | Sell | 8312026 | 172.79 | 9,307 | 1,608,143 | 10,789,437 | Form |
| 4 | Woolson, Daniel | VP, GM-Infusion Capital | Direct | Sell | 8132026 | 181.33 | 5,417 | 982,265 | 3,093,852 | Form |
| 5 | Sousa, Ben | Chief Information Officer | Direct | Sell | 8122026 | 178.32 | 2,250 | 401,209 | 548,498 | Form |
| 6 | Voigtlander, Christian B | Chief Operating Officer | Direct | Sell | 8112026 | 182.93 | 8,929 | 1,633,404 | 6,837,468 | Form |
| 7 | Finney, Elisha W | Direct | Sell | 8112026 | 182.48 | 378 | 68,978 | 888,869 | Form | |
| 8 | Woolson, Daniel | President | Direct | Sell | 5222026 | 132.21 | 2,123 | 280,685 | 2,971,980 | Form |
| 9 | Sanzone, Virginia Ruth | VP, General Counsel | Direct | Sell | 5152026 | 124.08 | 2,447 | 303,624 | 2,414,597 | Form |
| 10 | Greenberg, David C | Direct | Sell | 5132026 | 122.91 | 2,424 | 297,934 | 978,364 | Form | |
| 11 | Woolson, Daniel | VP, GM-Infusion Capital | Direct | Sell | 11252025 | 152.35 | 2,897 | 441,364 | 1,721,123 | Form |
| 12 | Finney, Elisha W | Direct | Sell | 11112025 | 140.42 | 1,285 | 180,440 | 560,978 | Form | |
| 13 | Sanzone, Virginia Ruth | VP, General Counsel | Direct | Sell | 11112025 | 142.34 | 930 | 132,381 | 776,634 | Form |
Investor Activity (13F)
Updated Sep 14, 2026Active managers (13F portfolio over $250M, at least 3 holdings) with a position over $5M that is either over 10% of their portfolio or held in a concentrated book of 50 or fewer total positions. Index/ETF, sovereign, bank, community-bank and charitable/donor-advised filers are excluded.
| Active Manager |
|---|
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.